Novavax (NASDAQ:NVAX) : Currently there are 6 street experts covering Novavax (NASDAQ:NVAX) stock. The most bullish and bearish price target for the stock is $17 and $6 respectively for the short term. The average price target of all the analysts comes to $13.15. The estimated standard deviation from the target is $3.81.
Shares of Novavax, Inc. rose by 5.21% in the last five trading days and 18.4% for the last 4 weeks. Novavax, Inc. is up 32.42% in the last 3-month period. Year-to-Date the stock performance stands at -13.35%. Also, Chardan Capital initiates coverage on Novavax (NASDAQ:NVAX). In the latest research report, Chardan Capital announces the target price to $5.75 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on April 4, 2016.
Novavax (NASDAQ:NVAX) has an average broker rating of 1.33, which is interpreted as a Strong Buy, as rated by 6 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Novavax (NASDAQ:NVAX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.28 and $7.14 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.27, notching a gain of 1.39% for the day. The total traded volume was 6,864,003 . The stock had closed at $7.17 on the previous day.
In an insider trading activity,The director of Novavax Inc, Evans Gary C sold 18,998 shares at $6.5 on June 6, 2016. The Insider selling transaction had a total value worth of $123,487. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).